A Study of Pexa-Vec (JX-594) Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma
| 対象疾患 | Carcinoma, Hepatocellular |
|---|---|
| 相 | 第2相 |
| スポンサー | Jennerex Biotherapeutics |
| ステータス | 完了 |
| 参加者数 | 25 名 |
| 介入（薬剤） | JX-594, Sorafenib |
| 開始日 | 2009年5月26日 |
| 完了日 | 2012年9月27日 |
| 結果公開日 | 2026年7月14日 |
概要
The purpose of this pilot safety study is to evaluate the safety and tolerability of JX-594 (Pexa-Vec) administered intravenously and intratumorally prior to standard sorafenib therapy.
Number of Participants With Treatment-Related Grade 3 and Grade 4 Adverse Events (AEs) and Serious Adverse Events (SAEs)
| JX-594 Followed by Sorafenib | 25 Participants |
|---|
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Treme — MedImmune LLC
- Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Live — National Cancer Institute (NCI)
- A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma — CStone Pharmaceuticals
- BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver C — Edward Kim
- Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hep — AstraZeneca
- Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Di — National Cancer Institute (NCI)